These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 35943054)

  • 21. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome.
    Stepan H; Hund M; Gencay M; Denk B; Dinkel C; Kaminski WE; Wieloch P; Semus B; Meloth T; Dröge LA; Verlohren S
    Hypertens Pregnancy; 2016 Aug; 35(3):295-305. PubMed ID: 27028698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Value of Angiogenic Markers in Pregnant Women With Chronic Hypertension.
    Binder J; Palmrich P; Kalafat E; Pateisky P; Öztürk E; Mittelberger J; Khalil A
    J Am Heart Assoc; 2021 Sep; 10(17):e020631. PubMed ID: 34459247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One-third of patients with eclampsia at term do not have an abnormal angiogenic profile.
    Chaiworapongsa T; Romero R; Gotsch F; Gomez-Lopez N; Suksai M; Gallo DM; Jung E; Levenson D; Tarca AL
    J Perinat Med; 2023 Jun; 51(5):652-663. PubMed ID: 36567427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
    Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Application of the concetrations ratio of soluble receptor tyrosine kinase type 1, and placental growth factor for short-term prediction and diagnosis of preeclampsia].
    Bubeníková Š; Cíchová A; Roubalová L; Durdová V; Vlk R
    Ceska Gynekol; 2016; 81(4):272-278. PubMed ID: 27882748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of the sFlt-1/PlGF (Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor) Ratio in Diagnosis or Misdiagnosis in Women With Clinical Diagnosis of Preeclampsia.
    Leaños-Miranda A; Graciela Nolasco-Leaños A; Ismael Carrillo-Juárez R; José Molina-Pérez C; Janet Sillas-Pardo L; Manuel Jiménez-Trejo L; Isordia-Salas I; Leticia Ramírez-Valenzuela K
    Hypertension; 2020 Sep; 76(3):892-900. PubMed ID: 32713272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decision Threshold for Kryptor sFlt-1/PlGF Ratio in Women With Suspected Preeclampsia: Retrospective Study in a Routine Clinical Setting.
    Andersen LLT; Helt A; Sperling L; Overgaard M
    J Am Heart Assoc; 2021 Sep; 10(17):e021376. PubMed ID: 34459248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Affinity-Enhanced Multimeric VEGF (Vascular Endothelial Growth Factor) and PlGF (Placental Growth Factor) Variants for Specific Adsorption of sFlt-1 to Restore Angiogenic Balance in Preeclampsia.
    Matin M; Mörgelin M; Stetefeld J; Schermer B; Brinkkoetter PT; Benzing T; Koch M; Hagmann H
    Hypertension; 2020 Oct; 76(4):1176-1184. PubMed ID: 32623922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Use of Soluble FMS-like Tyrosine Kinase 1/Placental Growth Factor Ratio in the Clinical Management of Pre-eclampsia.
    Govender N; Moodley J; Naicker T
    Afr J Reprod Health; 2018 Dec; 22(4):135-143. PubMed ID: 30632730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio.
    Villalaín C; Herraiz I; Valle L; Mendoza M; Delgado JL; Vázquez-Fernández M; Martínez-Uriarte J; Melchor Í; Caamiña S; Fernández-Oliva A; Villar OP; Galindo A
    J Am Heart Assoc; 2020 Apr; 9(7):e015548. PubMed ID: 32248765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of adverse maternal outcomes of early severe preeclampsia.
    Mirkovic L; Tulic I; Stankovic S; Soldatovic I
    Pregnancy Hypertens; 2020 Oct; 22():144-150. PubMed ID: 32979729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors.
    Lim JH; Kim SY; Park SY; Yang JH; Kim MY; Ryu HM
    Obstet Gynecol; 2008 Jun; 111(6):1403-9. PubMed ID: 18515525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
    Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
    Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia.
    Tang P; Xu J; Xie BJ; Wang QM
    Hypertens Pregnancy; 2017 Feb; 36(1):48-52. PubMed ID: 27834501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of sFlt-1/PlGF ratio in preeclampsia : a monocentric retrospective analysis].
    Verbeurgt L; Chantraine F; De Marchin J; Minon JM; Nisolle M
    Rev Med Liege; 2017 Sep; 72(9):393-398. PubMed ID: 28892314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1).
    Neuman RI; Baars MD; Saleh L; Broekhuizen M; Nieboer D; Cornette J; Schoenmakers S; Verhoeven M; Koch BCP; Russcher H; van den Berg SAA; van den Meiracker AH; Visser W; Danser AHJ
    Hypertension; 2022 Jun; 79(6):1297-1307. PubMed ID: 35341328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First and Second Trimester Serum sFlt-1/PlGF Ratio and Subsequent Preeclampsia: A Systematic Review.
    Yusuf AM; Kahane A; Ray JG
    J Obstet Gynaecol Can; 2018 May; 40(5):618-626. PubMed ID: 28927814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Placental Growth Factor and Soluble, Fms-Like Tyrosine Kinase-1 in Preeclampsia: A Case-Cohort (PEARL) Study.
    Fillion A; Guerby P; Lachance C; Comeau MP; Bussières MC; Doucet-Gingras FA; Zérounian S; Demers S; Laforest G; Menzies D; Bujold E
    J Obstet Gynaecol Can; 2020 Oct; 42(10):1235-1242. PubMed ID: 32718871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiogenic markers during preeclampsia: Are they associated with hypertension 1 year postpartum?
    Neuman RI; Figaroa AMJ; Nieboer D; Saleh L; Verdonk K; Danser AHJ; Duvekot HJJ; van den Meiracker AH; Roeters van Lennep J; Visser W
    Pregnancy Hypertens; 2021 Mar; 23():116-122. PubMed ID: 33321329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction.
    Dymara-Konopka W; Laskowska M; Grywalska E; Hymos A; Błażewicz A; Leszczyńska-Gorzelak B
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.